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SUMMARY 
SARS-CoV-2 is a recently identified coronavirus that causes the respiratory disease known as 
COVID-19. Despite the urgent need, we still do not fully understand the molecular basis of 
SARS-CoV-2 pathogenesis. Here, we comprehensively define the interactions between SARS-
CoV-2 proteins and human RNAs. NSP16 binds to the mRNA recognition domains of the U1 
and U2 splicing RNAs and acts to suppress global mRNA splicing upon SARS-CoV-2 infection. 
NSP1 binds to 18S ribosomal RNA in the mRNA entry channel of the ribosome and leads to 
global inhibition of mRNA translation upon infection. Finally, NSP8 and NSP9 bind to the 7SL 
RNA in the Signal Recognition Particle and interfere with protein trafficking to the cell 
membrane upon infection. Disruption of each of these essential cellular functions acts to 
suppress the interferon response to viral infection. Our results uncover a multipronged strategy 
utilized by SARS-CoV-2 to antagonize essential cellular processes to suppress host defenses. 
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INTRODUCTION 
Coronaviruses are a family of viruses with notably large single-stranded RNA genomes and 
broad species tropism among mammals(Graham and Baric, 2010). Recently, a coronavirus, 
SARS-CoV-2, was discovered to cause the severe respiratory disease known as COVID-19. It is 
highly transmissible within human populations and its spread has resulted in a global pandemic 
with more than a million deaths to date(Andersen et al., 2020; Zou et al., 2020). We do not fully 
understand the molecular basis of infection and pathogenesis of this virus in human cells. 
Accordingly, there is an urgent need to understand these mechanisms to guide the development 
of therapeutics.  
SARS-CoV-2 encodes 27 proteins with diverse functional roles in viral replication and 
packaging(Bar-On et al., 2020; Wang et al., 2020). These include 4 structural proteins: the 
nucleocapsid (N, which binds the viral RNA), and the envelope (E), membrane (M), and spike 
(S) proteins, which are integral membrane proteins. In addition, there are 16 non-structural 
proteins (NSP1-16) which encode the RNA-directed RNA polymerase, helicase, and other 
components required for viral replication(da Silva et al., 2020). Finally, there are 7 accessory 
proteins (ORF3a-8) whose function in viral replication or packaging remain largely 
uncharacterized(Chen and Zhong, 2020; Finkel et al., 2020).  
As obligate intracellular parasites, viruses require host cell components to translate and transport 
their proteins and to assemble and secrete viral particles(Maier et al., 2016). Upon viral infection, 
the mammalian innate immune system acts to rapidly detect and block viral infection at all stages 
of the viral life cycle(Chow et al., 2018; Jensen and Thomsen, 2012; Wilkins and Gale, 2010). 
The primary form of intracellular viral surveillance engages the interferon pathway, which 
amplifies signals resulting from detection of intracellular viral components to induce a systemic 
type I interferon response upon infection(Stetson and Medzhitov, 2006). Specifically, cells 
contain various RNA sensors (such as RIG-I and MDA5) that detect the presence of viral RNAs, 
promote nuclear translocation of the transcription factor IRF3 leading to transcription, 
translation, and secretion of interferon (e.g. IFN-α and IFN-β). Binding of interferon to cognate 
cell-surface receptors leads to transcription and translation of hundreds of antiviral genes.  
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In order to successfully replicate, viruses employ a range of strategies to counter host antiviral 
responses(Beachboard and Horner, 2016). In addition to their essential roles in the viral life 
cycle, many viral proteins also antagonize core cellular functions in human cells to evade host 
immune responses. For example, human cytomegalovirus (HCMV) encodes proteins that inhibit 
class 1 Major Histocompatibility (MHC) display on the cell surface by retaining MHC proteins 
in the endoplasmic reticulum(Miller et al., 1998), polioviruses encode proteins that degrade 
translation initiation factors (eIF4G) to prevent translation of 5’-capped host mRNAs(Kempf and 
Barton, 2008; Lloyd, 2006), and influenza A encodes a protein that modulates mRNA splicing to 
degrade the mRNA that encodes RIG-I(Kochs et al., 2007; Zhang et al., 2018). 
Suppression of the interferon response has recently emerged as a major clinical determinant of 
COVID-19 severity(Zhang et al., 2020), with almost complete loss of secreted IFN 
characterizing the most severe cases(Hadjadj et al., 2020). The extent to which SARS-CoV-2 
suppresses the interferon response is a key characteristic that distinguishes COVID-19 from 
SARS and MERS(Lokugamage et al., 2020). Several strategies have been proposed for how the 
related SARS- and MERS-causing viruses may hijack host cell machinery and evade immune 
detection, including repression of host mRNA transcription in the nucleus(Canton et al., 2018), 
degradation of host mRNA in the nucleus and cytoplasm(Kamitani et al., 2009; Lokugamage et 
al., 2015), and inhibition of host translation(Nakagawa et al., 2018). Nonetheless, the extent to 
which SARS-CoV-2 uses these or other strategies, and how they may be executed at a molecular 
level remains unclear.  
Understanding the interactions between viral proteins and components of human cells is essential 
for elucidating their pathogenic mechanisms and for development of effective therapeutics. 
Because SARS-CoV-2 is an RNA virus and many of its encoded proteins are known to bind 
RNA(Sola et al., 2011), we reasoned that these viral proteins may interact with specific human 
mRNAs (critical intermediates in protein production) or non-coding RNAs (critical structural 
components of diverse cellular machines) to promote viral propagation.  
Here, we comprehensively define the interactions between each SARS-CoV-2 protein and 
human RNAs. We show that 10 viral proteins form highly specific interactions with mRNAs or 
ncRNAs, including those involved in progressive steps of host cell protein production. We show 
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that NSP16 binds to the mRNA recognition domains of the U1 and U2 RNA components of the 
spliceosome and acts to suppress global mRNA splicing in SARS-CoV-2-infected human cells. 
We find that NSP1 binds to a precise region on the 18S ribosomal RNA that resides in the 
mRNA entry channel of the initiating 40S ribosome. This interaction leads to global inhibition of 
mRNA translation upon SARS-CoV-2 infection of human cells. Finally, we find that NSP8 and 
NSP9 bind to discrete regions on the 7SL RNA component of the Signal Recognition Particle 
(SRP) and interfere with protein trafficking to the cell membrane upon infection. We show that 
disruption of each of these essential cellular functions acts to suppress the type I interferon 
response to viral infection. Together, our results uncover a multipronged strategy utilized by 
SARS-CoV-2 to antagonize essential cellular processes and robustly suppress host immune 
defenses. 
 
RESULTS 
Comprehensive mapping of SARS-CoV-2 protein binding to human RNAs 
We cloned all 27 of the known SARS-CoV-2 viral proteins into mammalian expression vectors 
containing an N-terminal HaloTag(Los et al., 2008) (Figure S1A, Methods), expressed each in 
HEK293T cells, and exposed them to UV light to covalently crosslink proteins to their bound 
RNAs. We then lysed the cells and purified each viral protein using stringent, denaturing 
conditions to disrupt any non-covalent associations and capture those with a UV-mediated 
interaction (Figure 1A, Methods). As positive and negative controls, we purified a known 
human RNA binding protein (PTBP1) and a metabolic protein (GAPDH) (Figure S1A-E). 
We successfully purified 26 of the 27 viral proteins (Figure S1A; full-length Spike was not 
soluble when expressed). We found that 10 viral proteins (NSP1, NSP4, NSP8, NSP9, NSP12, 
NSP15, NSP16, ORF3b, N, and E protein) bind to specific host RNAs (p-value < 0.001, Figure 
1B, Table S1), including 6 structural ncRNAs and 142 mRNAs (Table S1). These include 
mRNAs involved in protein translation (e.g. COPS5, EIF1, and RPS12,), protein transport 
(ATP6V1G1, SLC25A6, and TOMM20), protein folding (HSPA5, HSPA6, and HSPA1B), 
transcriptional regulation (YY1, ID4, and IER5), and immune response (JUN, AEN, and 
Jo
urn
al 
Pr
e-p
roo
f
 6
RACK1)  (FDR < 0.05, Figure 1B, S1F). Importantly, the observed interactions are highly 
specific for each viral protein, and each protein binds to a precise region within each RNA 
(Figures 1C, S1F).  
Using these data, we identified several viral proteins that interact with structural ncRNA 
components of the spliceosome (U1 and U2 snRNA), the ribosome (18S and 28S rRNA), and the 
Signal Recognition Particle (7SL) (Figure 1B). Because these molecular machines are essential 
for three essential steps of protein production – mRNA splicing, translation, and protein 
trafficking – we focused on their interactions with viral proteins to understand their functions and 
mechanisms in SARS-CoV-2 pathogenesis. 
 
NSP16 binds to the pre-mRNA recognition domains of the U1 and U2 snRNAs 
After transcription in the nucleus, nascent pre-mRNAs are spliced to generate mature mRNAs 
which are translated into protein. Splicing is mediated by a complex of ncRNAs and proteins 
known as the spliceosome. Specifically, the U1 small nuclear RNA (snRNA) hybridizes to the 5’ 
splice site at the exon-intron junction and the U2 snRNA hybridizes to the branchpoint site 
within the intron to initiate splicing of virtually all human mRNAs(Séraphin et al., 1988). 
We identified a highly specific interaction between the NSP16 viral protein and the U1 and U2 
snRNAs (Figure 1B).  Because U1 and U2 are small RNAs (164 and 188 nucleotides, 
respectively), we noticed strong enrichment of NSP16-associated reads across the entire length 
of each. To more precisely define the binding sites, we exploited the well-described tendency of 
reverse transcriptase to preferentially terminate when it encounters a UV-crosslinked protein on 
RNA(Konig et al., 2010) (Figures 1A, S1D). We determined that NSP16 binds to the 5’ splice 
site recognition sequence of U1 (Figures 2A-B, S2A-B) and the branch point recognition site of 
U2 (Figure 2C-D, S2C-D). These binding sites are highly specific to NSP16 relative to all of the 
other viral and human proteins (Figure 1B, S2A, 2C). Consistent with its interaction with 
U1/U2, we observed that NSP16 localizes within the nucleus upon SARS-CoV-2 infection 
(Figure 2E, S2E-F) and when expressed in human cells (Figure S2G).  
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NSP16 disrupts global mRNA splicing upon SARS-CoV-2 infection 
Based on the locations of the NSP16 binding sites relative to the mRNA recognition domains of 
the U1/U2 spliceosomal components, we hypothesized that NSP16 might disrupt splicing of 
newly transcribed genes (Figure 2F). To test this, we co-expressed NSP16 in human cells along 
with a splicing reporter derived from IRF7 (an exon-intron-exon minigene) fused to 
GFP(Majumdar et al., 2018). In this system, if the reporter is spliced, then GFP is made; if not, 
translation is terminated (via a stop codon present within the first intron) and GFP is not 
produced (Figure 3A). We observed a >3-fold reduction in GFP levels in the presence of NSP16 
compared to a control human protein (Figures 3B, S3A). 
To explore whether NSP16 has a global impact on splicing of endogenous mRNAs, we measured 
the splicing ratio of each gene using nascent RNA sequencing. Specifically, we metabolically 
labeled nascent RNA by feeding cells for 20 minutes with 5-ethynyl uridine (5EU), purified and 
sequenced 5EU-labeled RNA, and quantified the proportion of unspliced fragments spanning the 
3’ splice site of each gene (Figure 3C, S3B). We observed a global increase in the fraction of 
unspliced genes in the presence of NSP16 compared to controls (Figure 3D, S3C,D).  
Given that NSP16 is sufficient to suppress global mRNA splicing, we expect that its expression 
in SARS-CoV-2-infected cells would result in a global mRNA splicing deficit. To test this, we 
infected human lung epithelial cells (Calu3) with SARS-CoV-2 and measured splicing levels of 
newly transcribed mRNAs compared to a mock infected control. As expected, we observed a 
global increase in the fraction of unspliced transcripts upon SARS-CoV-2 infection, with ~90% 
of measured genes showing increased intron retention (Figure 3E, S3E). 
Together these results indicate that NSP16 binds to the splice site and branch point sites of 
U1/U2 to suppress global mRNA splicing in SARS-CoV-2 infected cells (Figure 3F). Although 
NSP16 is known to act as an enzyme that deposits 2’-O-methyl modifications on viral 
RNAs(Decroly et al., 2011), our results demonstrate that it also acts as a host virulence factor. 
Global disruption of mRNA splicing may act to decrease host protein and mRNA levels by 
triggering nonsense-mediated decay of improperly spliced mRNAs(Kurosaki et al., 2019). 
Consistent with this, we observed a strong global decrease in steady-state mRNA levels (relative 
to ncRNA levels) upon SARS-CoV-2 infection (Figure S3F).  
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Inhibition of mRNA splicing suppresses host interferon response to viral infection 
Because many of the key genes stimulated by interferon (IFN) are spliced, we reasoned that 
mRNA splicing would be critical for a robust IFN response. To test this, we utilized a reporter 
line engineered to express alkaline phosphatase upon IFN signaling (mimicking an antiviral 
response gene). This IFN Stimulated Gene (ISG) reporter line can be stimulated using IFN-β and 
assayed for reporter induction. We observed strong repression of this IFN responsive gene upon 
expression of NSP16 (Figure 3G) and upon addition of a small molecule that interferes with 
spliceosomal assembly (Figure S3G). These results demonstrate that one outcome of NSP16-
mediated inhibition of mRNA splicing is to reduce the host cells’ innate immune response to 
viral recognition. Consistent with such a role, we observed an increase in intron retention within 
multiple IFN-responsive genes (such as ISG15 and RIG-I) upon SARS-CoV-2 infection (Figure 
3H, S3H-I).  
 
NSP1 binds to 18S ribosomal RNA in the mRNA entry channel of the 40S subunit 
Once exported to the cytoplasm, spliced mRNA is translated into protein on the ribosome. 
Initiation of translation begins with recognition of the 5’ cap by the small 40S subunit (which 
scans the mRNA to find the first start codon). We observed that NSP1 binds exclusively to the 
18S ribosomal RNA (Figure 1B and S4A) – the structural RNA component of the 40S 
ribosomal subunit.  
Several roles for NSP1 have been reported in SARS-CoV and MERS-CoV including roles in 
viral replication, translational inhibition, transcriptional inhibition, mRNA degradation, and cell 
cycle arrest(Brockway and Denison, 2005; Kamitani et al., 2009; Lokugamage et al., 2015; 
Narayanan et al., 2015). One of the reported roles for NSP1 in SARS-CoV is that it can associate 
with the 40S ribosome to inhibit host mRNA translation(Kamitani et al., 2009; Tanaka et al., 
2012), yet it remains unknown whether this association is due to interaction with the ribosomal 
RNA, protein components of the ribosome, or other auxiliary ribosomal factors. Accordingly, the 
mechanisms by which NSP1 acts to suppress protein production remain elusive.  
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We mapped the location of NSP1 binding to a 37 nucleotide region corresponding to Helix 18 
(Figure 4A), adjacent to the mRNA entry channel(Simonetti et al., 2020) (Figure 4B). The 
interaction would position NSP1 to disrupt 40S mRNA scanning and prevent translation 
initiation (Figure 4B), and disrupt tRNA recruitment to the 80S ribosome and block protein 
production (Figure S4B). Interestingly, the NSP1 binding site includes the highly conserved 
G626 nucleotide which monitors the minor groove of the codon-anticodon helix for tRNA 
binding fidelity(Ogle et al., 2001). We noticed that the C-terminal region of NSP1 has similar 
structural regions to SERBP1(Brown et al., 2018) and Stm1(Ben-Shem et al., 2011a), two known 
ribosome inhibitors that bind within the mRNA entry channel to preclude mRNA access (Figure 
S4C). Consistent with this, a recent cryo-EM structure confirms that NSP1 binds to these same 
nucleotides of 18S within the mRNA entry channel(Thoms et al., 2020). 
NSP1 suppresses global translation of host mRNAs upon SARS-CoV-2 infection 
Given the location of NSP1 binding on the 40S ribosome, we hypothesized that it could suppress 
global initiation of mRNA translation. To test this, we performed in vitro translation assays of a 
GFP reporter in HeLa cell lysates and found that addition of NSP1 led to potent inhibition of 
translation (Figure S4D). We observed a similar NSP1-mediated translational repression when 
we co-expressed NSP1 and a GFP reporter gene in HEK293T cells (Figure 4C-D). In contrast, 
we did not observe this inhibition when we expressed other SARS-CoV-2 proteins (NSP8, 
NSP9, M) or human proteins (GAPDH) (Figure 4D).  
To determine if NSP1 leads to translational inhibition of endogenous proteins in human cells, we 
used a technique called Surface Sensing of Translation (SUnSET) to measure global protein 
production levels(Schmidt et al., 2009). In this assay, translational activity is measured by the 
level of puromycin incorporation into elongating polypeptides (Figure S4E). We observed a 
strong reduction in the level of global puromycin integration in cells expressing NSP1 compared 
to cells expressing GFP (Figure S4F-G).  
Because NSP1 expression is sufficient to suppress global mRNA translation in human cells, we 
hypothesized that SARS-CoV-2 infection would also suppress global translation. To test this, we 
infected a human lung epithelial (Calu3) or monkey kidney (Vero) cell line with SARS-CoV-2 
and measured nascent protein synthesis levels using SUnSET. We observed a strong reduction of 
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global puromycin integration upon SARS-CoV-2 infection in both cell types (Figure 4E-F, 
Figure S4H-I).  
To explore whether NSP1 binding to 18S rRNA is critical for translational repression, we 
generated a mutant NSP1 in which two positively charged amino acids (K164 and H165) in the 
C-terminal domain were replaced with alanine residues (Figure S4C)(Narayanan et al., 2008). 
We observed a complete loss of in vivo contacts with 18S (Figure 4G); because this mutant 
disrupts ribosome contact, we refer to it as NSP1∆RC. We co-expressed GFP and NSP1∆RC in 
HEK293T cells and found that the mutant fails to inhibit translation (Figure 4H and S4J). In 
contrast, mutations to the positively charged amino acids at positions 124/125 do not impact 18S 
binding (Figure 4G) or the ability to inhibit translation (Figure 4H).  
Together, these results demonstrate that NSP1 binds within the mRNA entry channel of the 
ribosome and that this interaction is required for translational inhibition of host mRNAs upon 
SARS-CoV-2 infection.  
 
NSP1-mediated translational inhibition suppresses host interferon response 
We explored whether NSP1 binding to 18S rRNA suppresses the ability of cells to respond to 
IFN-β stimulation upon viral infection. We transfected ISG reporter cells with NSP1, stimulated 
with IFN-β, and observed robust repression of the IFN responsive gene (>6-fold, Figure 4I). To 
confirm that this NSP1-mediated repression occurs in human cells upon activation of double 
stranded RNA (dsRNA)-sensing pathways typically triggered by viral infection, we treated a 
human lung epithelial cell line (A549) with poly(I:C), a molecule that is structurally similar to 
dsRNA and known to induce an antiviral innate immune response(Alexopoulou et al., 2001; 
Kato et al., 2006) (Figure S4K). We observed a marked downregulation of IFN-β protein and 
endogenous IFN-β responsive mRNAs in the presence of NSP1, but not in the presence of 
NSP1∆RC (Figure S4L, M). These results demonstrate that NSP1, through its interaction with 
18S rRNA, suppresses the innate immune response to viral recognition (Figure 4J). 
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The viral 5’ leader protects mRNA from NSP1-mediated translational inhibition 
Because NSP1 blocking the mRNA entry channel would impact both host and viral mRNA 
translation, we explored how translation of viral mRNAs is protected from NSP1-mediated 
translational inhibition. Many viruses contain 5’ untranslated regions that regulate viral gene 
expression and translation(Gaglia et al., 2012); all SARS-CoV-2 encoded subgenomic RNAs 
contain a common 5’ leader sequence that is added during negative strand synthesis(Kim et al., 
2020b). We explored whether the leader sequence protects viral mRNAs from translational 
inhibition by fusing the viral leader sequence to the 5’ end of GFP or mCherry reporter genes 
(Figure S5A). We found that NSP1 fails to suppress translation of these leader-containing 
mRNAs (Figure 5A-B, S5B). We dissected the leader sequence and found that the first stem 
loop (SL1) is sufficient to prevent translational suppression upon NSP1 expression (Figure 5C) 
or SARS-CoV-2 infection (Figure 5D). 
We considered three models for how the leader could protect viral mRNAs: (i) it could compete 
with the ribosome for NSP1 binding, (ii) it could directly recruit free ribosomes or (iii) NSP1 
could bind to the leader independently of its ribosome interaction to allosterically modulate the 
NSP1-ribosome interaction. We reasoned that if the leader competes for NSP1 binding or 
directly recruits free ribosomes, then the presence of SL1 should be sufficient for protection, 
regardless of its precise position in the 5’ UTR. In contrast, if the leader allosterically modulates 
ribosome binding then the spacing between the 5’ cap (which is bound to NSP1-40S) and SL1 
would be critical for protection. To distinguish between these models, we swapped the location 
of SL1 and SL2 in the 5’ leader or inserted 5 nucleotides between the 5’ cap and SL1 (Figure 
S5C) and found that both mutants ablate protection (Figure 5E, S5D).  
These results indicate that an mRNA requires the 5’ leader to be precisely positioned relative to 
the NSP1-bound 40S ribosome to enable translational initiation (Figure 5F). While many 
aspects of this allosteric model remain to be explored, it would explain how leader-mediated 
protection can occur on an mRNA only when present in cis. Moreover, this model suggests that 
NSP1 might also act to further increase viral mRNA translation by actively recruiting the 
ribosome to its own mRNAs. Consistent with this, we observe a consistent ~20% increase in 
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translation of leader-containing reporter levels upon viral infection (Figure 5D) or expression of 
NSP1 (Figure S5E).  
 
NSP8 and NSP9 bind to the 7SL RNA component of the Signal Recognition Particle 
Upon engaging the start codon in an mRNA, the 60S subunit of the ribosome is recruited to form 
the 80S ribosome which translates mRNA. The Signal Recognition Particle (SRP) is a 
universally conserved complex that binds to the 80S ribosome and acts to co-translationally scan 
the nascent peptide to identify hydrophobic signal peptides present in integral membrane proteins 
and proteins secreted from the plasma membrane(Akopian et al., 2013). When these are 
identified, SRP triggers ribosome translocation to the endoplasmic reticulum (ER) to ensure 
proper folding and trafficking of these proteins to the cell membrane(Akopian et al., 2013). 
We identified two viral proteins – NSP8 and NSP9 – that bind at distinct and highly specific 
regions within the S-domain of the 7SL RNA scaffold of SRP (Figure 6A, S6A). NSP8 interacts 
with 7SL in the region bound by SRP54 (the protein responsible for signal peptide recognition, 
SRP-receptor binding, and ribosome translocation)(Akopian et al., 2013; Holtkamp et al., 2012) 
(Figure 6B). NSP9 binds to 7SL in the region that is bound by the SRP19 protein (Figure 6B), 
which is required for proper folding and assembly of SRP (including proper loading of  
SRP54)(Akopian et al., 2013).  
Because SRP scans nascent peptides co-translationally, we were intrigued to find that NSP8 also 
forms a highly specific interaction with 28S rRNA (the structural component of the 60S subunit) 
(Figure 6C, S6B). The binding site on 28S rRNA corresponds to the largest human-specific 
expansion segment within the ribosome, referred to as ES27(Parker et al., 2018). ES27 is highly 
dynamic, and thus has not been resolved in most ribosome structures(Zhang et al., 2014). 
However, when engaged by specific factors, ES27 can become ordered, and was recently shown 
to be capable of interacting with the ribosome exit tunnel, adjacent to the 60S binding site of 
SRP (Figure 6D, S6C)(Wild et al., 2020). 
Together, these observations suggest that NSP8 and NSP9 bind to the co-translational SRP 
complex. Consistent with this, we find that NSP8 and NSP9 localize broadly throughout the 
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cytoplasm when expressed in human cells (Figure S6D) or upon SARS-CoV-2 infection (Figure 
S6E-F). 
 
NSP8 and NSP9 suppress protein integration into the cell membrane 
Because NSP8 and NSP9 binding on 7SL are positioned to disrupt SRP function, we 
hypothesized that they may alter translocation of secreted and integral membrane proteins 
(Figure S7A).  
To test this, we expressed an SRP-dependent membrane protein (Nerve Growth Factor Receptor, 
NGFR(Izon et al., 2001a)) fused via an Internal Ribosome Entry Site (IRES) to a non-membrane 
GFP (Figure S7F). In this system, if a perturbation specifically affects membrane protein levels 
we expect to see a decrease in the ratio of membrane to non-membrane protein levels. To ensure 
that the NGFR reporter accurately reports on SRP function, we treated HEK293T cells with 
siRNAs against SRP54 or SRP19 and found that both lead to a dramatic reduction of the NGFR-
membrane protein relative to the non-membrane GFP protein (Figure S7B). Similarly, we found 
that expression of NSP8 and NSP9 (alone or together) lead to a striking reduction in expression 
of NGFR relative to GFP (Figure 7A). Expression of control proteins did not specifically impact 
NGFR levels (Figure 7A, S7B). 
To determine if there is a global effect on membrane protein levels, we utilized the SUnSET 
method to measure puromycin levels in membrane proteins using flow cytometry (see Methods). 
We confirmed that disruption of SRP leads to a global reduction in puromycin levels in the cell 
membrane (Figure S7C). We observed a comparable global reduction of puromycin-labeled 
membrane proteins upon expression of NSP8 or NSP9 individually or together, but not with 
control proteins (Figure 7B, S7C). 
 
SARS-CoV-2 infection suppresses protein integration into the cell membrane 
Because NSP8 and NSP9 are each sufficient to suppress protein integration into the cell 
membrane, we anticipate that SARS-CoV-2 infection would lead to similar suppression. 
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However, determining whether SARS-CoV-2 infection specifically impacts membrane protein 
expression is confounded by the fact that NSP1 inhibits translation of membrane and non-
membrane proteins upon infection. 
To address this, we co-expressed a membrane protein reporter (NGFR) containing the 5’ viral 
leader along with a non-membrane GFP reporter containing the viral leader. Upon viral 
infection, we observed a strong reduction of membrane protein levels (Figure 7C), but no 
reduction in non-membrane GFP levels (Figure 5D). To ensure that these effects are specific to 
SARS-CoV-2 infected cells, we separated individual cells within the infected population into 
those expressing the viral Spike protein (S+) and those not expressing the protein (S-). We found 
that the shift in membrane protein levels only occurs in S+ cells (Figure 7D), while the S- 
population resembled the mock infected samples (Figure 7C). We observed a strong relationship 
between the level of Spike protein – likely reflecting the amount of viral replication within each 
cell – and the level of membrane protein suppression (Figure 7C). We observed this membrane 
protein-specific decrease upon infection of human lung epithelial (Calu3, Figure S7D) and  
monkey kidney (Vero, Figure 7C-D) cell lines. 
Together, these results demonstrate that NSP8 and NSP9 bind to 7SL to disrupt SRP function 
and suppress membrane protein trafficking in SARS-CoV-2 infected cells. Although NSP8 and 
NSP9 are thought to be components of the viral replication machinery(Sutton et al., 2004), our 
results indicate that they play an additional role as host virulence factors. Because viral 
membrane proteins also require trafficking to the ER, viral disruption of SRP might negatively 
impact viral propagation, unless viral proteins are trafficked in an SRP-independent manner 
(Figure S7E) or if NSP8/9 selectively impacts host (but not viral) proteins. 
 
Viral disruption of protein trafficking suppresses interferon response 
Next we explored how disruption of SRP might be advantageous for viral propagation. Because 
secretion of IFN and other cytokines is dependent on the SRP complex for secretion (Figure 
S7F), a central component of the IFN response is dependent on SRP. Accordingly, we 
hypothesized that NSP8/9-mediated viral suppression of SRP would act to suppress the IFN 
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response upon infection. To test this, we co-expressed NSP8 and NSP9 and observed a 
significant reduction in the IFN response relative to a control protein (Figure S7G).  
Together, these results suggest that SARS-CoV-2 mediated suppression of SRP-dependent 
protein secretion enables suppression of host immune defenses (Figure 7E). Interestingly, many 
proteins involved in anti-viral immunity – including most cytokines and class I major 
histocompatibility complex – are membrane-anchored or secreted, and are known to use the SRP 
pathway for transport(Vermeire et al., 2014) (Figure S7F), suggesting that there may be other 
effects of SRP pathway inhibition on SARS-CoV-2 pathogenesis. 
 
 
DISCUSSION 
We identified several pathogenic functions of SARS-CoV-2 in human cells - including global 
inhibition of host mRNA splicing, protein translation, and membrane protein trafficking - and 
described the molecular mechanisms by which the virus acts to disrupt these essential cell 
processes. Interestingly, all of the viral proteins involved (NSP1, NSP8, NSP9, and NSP16) are 
produced in the first stage of the viral life cycle, prior to generation of double stranded RNA 
(dsRNA) products during viral genome replication. Because dsRNA is detected by host immune 
sensors and triggers the type I interferon response, disruption of these cellular processes would 
allow the virus to replicate its genome while minimizing the host innate immune response.  
Disruption of these three non-overlapping steps of protein production may represent a multi-
pronged mechanism that synergistically acts to suppress the host antiviral response (Figure 7F). 
Specifically, the IFN response is usually boosted >1,000-fold upon viral detection (through 
amplification and feedback, Figure S4K), yet each individual mechanism impacts IFN levels on 
the order of ~5-10-fold. Accordingly, if each independent mechanism impacts IFN levels 
moderately, the three together may be able to achieve dramatic suppression of IFN (103=1,000-
fold). This multi-pronged mechanism may explain the molecular basis for the potent suppression 
of IFN observed in severe COVID-19 patients.  
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Interferon is emerging not only as a determinant of disease severity, but also a potential 
treatment option(Zhou et al., 2020). As such, our work identifies several therapeutic 
opportunities for boosting IFN levels upon SARS-CoV-2 infection. For example, disrupting the 
interaction between NSP1 and 18S rRNA could allow cells to detect and respond to viral 
infection. Because many small-molecule drugs target ribosomal RNAs(Liaud et al., 2019), it may 
be possible to develop drugs to block the NSP1-18S and other interactions. Additionally, 
disrupting the 5’ viral leader may be a potent antiviral strategy since it is critical for translation 
of all viral proteins. Because SL1 is a structured RNA, it may be possible to design small 
molecules that specifically bind this structure to suppress viral protein production(Hermann, 
2016). 
Viral suppression of these cellular functions is not exclusive to the IFN response and will also 
impact other spliced, translated, secreted, and membrane proteins. Many proteins involved in 
anti-viral immunity are spliced and/or membrane-anchored or secreted. For example, class I 
major histocompatibility complex (MHC), which is critical for antigen presentation to CD8 T 
cells at the cell surface of infected cells(Hansen and Bouvier, 2009). By antagonizing membrane 
trafficking, SARS-CoV-2 may prevent viral antigens from being presented on MHC and allow 
infected cells to escape T-cell recognition and clearance. In this way, interference with these 
essential cellular processes might further aid SARS-CoV-2 in evading the host immune response.  
More generally, we expect that insights gained from the SARS-CoV-2 protein-RNA binding 
maps will be critical for exploring additional viral mechanisms. Specifically, we identified many 
other interactions, including highly specific interactions with mRNAs. For example, NSP12 
binds to the JUN mRNA (Figure S1E) which encodes the critical immune transcription factor c-
Jun which is activated in response to multiple cytokines and immune signaling pathways(Weston 
and Davis, 2007). We also identified an interaction between NSP9 and the start codon of the 
mRNA that encodes COPS5 (Figure 1C), the enzymatic subunit of the COP9 Signalosome 
complex which regulates protein homeostasis(Cope and Deshaies, 2003), suggesting that it might 
disrupt its translation. Interestingly, COPS5 (also known as JAB1) is known to bind and stabilize 
c-Jun protein levels(Claret et al., 1996) and several viruses are known to disrupt this 
protein(Lungu et al., 2008; Oh et al., 2006; Tanaka et al., 2006). While it remains unknown what, 
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if any, role these interactions play in virally infected cells, the specificity suggests that they may 
provide a selective advantage for viral propagation. 
Together, our results demonstrate that global mapping of RNA binding by viral proteins could 
enable rapid characterization of mechanisms for emerging pathogenic RNA viruses.  
Limitations of Study 
We note several limitations of our current study that will need to be explored in future work. (i) 
Our mapping experiments were performed in uninfected human cells expressing tagged viral 
proteins. Accordingly, it remains possible that our maps may not fully capture all of the 
interactions that occur when human cells are infected, such as interactions that occur with viral-
induced RNAs, in specific viral compartments, or that require multiple viral proteins. (ii) While 
we characterized the functional and mechanistic roles of several viral proteins and structural 
ncRNAs, we did not explore what roles viral protein interactions with mRNAs might play. (iii) 
How the virus disrupts fundamental cellular processes while still maintaining its own production 
is still largely undefined. While we showed that the 5' leader is sufficient to relieve translational 
inhibition by NSP1, we still do not fully understand how this protection occurs and specifically 
how NSP1 might interact with the viral leader or allosterically modulate ribosome binding. 
Similarly, viral membrane proteins are dependent on trafficking to the ER and how NSP8/9 
might selectively impact ER translocation of host – but not viral – proteins remains to be 
explored. (iv) While we showed that viral disruption of these essential cellular functions can 
suppress IFN, what other roles host cell shutdown might play in viral pathogenesis and in 
suppressing other aspects of anti-viral immunity, including possible roles in adaptive immune 
responses, have not been explored. 
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FIGURE LEGENDS 
Figure 1.  Global RNA binding maps of SARS-CoV-2 proteins. (A) Schematic of our 
approach. (B) Enrichment heatmap of each SARS-CoV-2 protein (rows) by significantly 
enriched 100 nucleotide RNA bins (columns, p-value<0.001 and enrichment > 3-fold, Methods). 
Shared colored bars indicate multiple bins within the same mRNA. For spacing reasons, the 82 
mRNAs bound by N-protein are displayed separately. (C) Examples of sequencing reads over 
specific mRNAs for viral proteins (red) relative to input RNA coverage (gray) are shown. 
Coding regions (thick lines) and untranslated regions (thin lines) are shown for each mRNA. See 
also Table S1. 
Figure 2. NSP16 binds to U1 and U2 at their mRNA recognition sites. (A) NSP16 enrichment 
of reverse transcription stop positions across each nucleotide of U1 (red) compared to a control 
protein (GAPDH - black). Red box (below the x-axis) represents most enriched nucleotide 
positions (U1:9-13 nts). Gray shaded box (overlay) outlines the position of the splice site 
recognition sequence. (B) Left: Structure of the pre-catalytic human spliceosome 
(PDB:6QX9)(Charenton et al., 2019) highlighting the location of NSP16 binding site (red 
spheres) relative to U1 (yellow ribbon) and mRNA (purple ribbon). Right: Schematic of the 
structure. (C) Enrichment across each nucleotide of U2 for NSP16 (red) and GAPDH (black). 
Red box demarcates most enriched nucleotide positions (U2:27-34 nts). Gray shaded box 
outlines the location of the branchpoint recognition sequence. (D) Structure of the pre-catalytic 
human spliceosome (PDB:6QX9)(Charenton et al., 2019) displaying NSP16 binding site (red 
spheres), U2 (orange), and mRNA (purple). (E) Mock (top) or SARS-CoV-2 infected (bottom) 
Vero E6 cells immunostained with a polyclonal antibody to NSP16 (left) or NSP1 (right). Imaris 
3D reconstruction of DAPI (nucleus) and NSP16 or NSP1 signal are shown for each protein. 
Signal contained within the 3D nuclear volume (blue) is shown in yellow and cytoplasmic signal 
in purple. Size bars are 3µm. (F) Model: NSP16 binding to U1/U2 can impact mRNA 
recognition during splicing.  
Figure 3. NSP16 suppresses host mRNA splicing. (A) Schematic of fluorescence reporter used 
to assay mRNA splicing. (B) GFP density plot of HEK293T cells expressing the GFP splicing 
reporter and either GAPDH (gray) or NSP16 (red). (C) Schematic of nascent RNA purification 
Jo
urn
l P
re-
pro
of
 21
method. (D) The % unspliced difference for each gene between HEK293T cells transfected with 
GAPDH (gray) or NSP16 (red). Plot represents the merge of four independent biological 
replicates; replicates plotted in Figure S4C. (E) Violin plot for SARS-CoV-2 infected human 
lung epithelial cells (MOI=0.01, 48 hours) compared to mock. Plot are merge of two biological 
replicates;  replicates plotted in Figure S4E. (F) Model: NSP16 binding to U1 and U2 can reduce 
overall mRNA and protein levels. (G) Expression of an interferon stimulated gene (ISG) reporter 
upon transfection with GAPDH (gray) or NSP16 (red) after stimulation with IFN-β. Three 
independent biological replicates, ** indicates p-value<0.01. (H) Example of nascent RNA 
sequencing at the intron of ISG15 (intron = line, exon = box) upon SARS-CoV-2 (red) or mock 
(gray) infection.  
Figure 4. NSP1 binds to 18S near the mRNA entry channel to suppress translation. (A) 
NSP1 enrichment across each nucleotide of 18S. Cyan box indicates the most enriched 
nucleotides of NSP1 binding (18S:607-644 nts). (B) The location of NSP1 binding (cyan 
spheres) relative to the known structure of 40S (gray) and mRNA (purple ribbon). Right: 
Schematic illustrating structure(Ameismeier et al., 2018) and how NSP1 binding would block 
mRNA entry. (C) Images of HEK293T cells co-expressing GFP reporter and GAPDH (top) or 
NSP1 (bottom). (D) Flow cytometry quantification (mean intensity) of GFP in the presence of 
GAPDH, NSP8/9, M, or NSP1 proteins. Three independent biological replicates per condition. 
(E) Puromycin incorporation (top) or total actin levels (bottom) measured in Calu3 cells infected 
with SARS-CoV-2 (MOI=0.01, 48h) or mock control (left 2 lanes). (F) The ratio of puromycin 
signal over total actin signal is plotted for each individual replicate. (G) Read enrichment on 18S 
for an independent replicate of NSP1 Wild Type, NSP1 R124A/K125A Mutant, and NSP1 
K164A/H165A (∆RC) Mutant. (H) Flow cytometry analysis of HEK293T cells transfected with 
GFP and NSP1∆RC mutant (gray), wild-type NSP1, or NSP1 R124A/K125A (cyan). (I) 
Quantification of IFN-β response in the presence of GAPDH (gray) or NSP1 (cyan). (J) 
Schematic of how NSP1 acts to suppress mRNA translation. In all panels, error bars represent 
standard deviation across biological replicates, dots represent individual values for each 
replicate, *p<0.05 and **p<0.01. 
Figure 5. The 5’ viral leader protects mRNA from NSP1-mediated translational inhibition. 
(A) Images of cells co-transfected with NSP1 and mCherry alone (- leader, top) or mCherry 
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fused to the SARS-CoV-2 leader (+ leader, bottom). (B) GFP (green) or mCherry (red) levels 
when fused to the viral leader (+leader, right) or lacking viral leader (-leader, left). (C) GFP 
reporter with no leader (left), full leader (middle), or stem loop 1 (SL1) upon NSP1 expression. 
(D) Calu3 cells expressing SL1 fused to GFP. Cells were mock or SARS-CoV-2 infected (MOI= 
0.1) and GFP expression was measured 24 hours post infection by flow cytometry. (E) GFP 
reporter containing SL1 (left), a swap of SL2 and SL1 (SL2-SL1), insertion of 5 nucleotides 
between the 5’ end and SL1 (+5nt-SL1), or no leader. GFP protein level was measured for each 
condition upon expression of NSP1. (F) Proposed model for how NSP1 binding to the viral 
leader can allosterically modulate NSP1 structure to protect mRNAs in cis. In all panels, error 
bars represent standard deviation across biological replicates, dots represent individual replicate 
values, * indicates p<0.05 and ** p<0.01. 
Figure 6. NSP8 and NSP9 bind to 7SL RNA of the Signal Recognition Particle. (A) 
Enrichment of reverse transcription stop positions across each nucleotide of 7SL is shown for 
NSP8 (blue) and NSP9 (red). Red (7SL:142-143 and 7SL: 149-151 nts) and blue (7SL:193-194 
nts) boxes demarcate the most enriched nucleotide positions. (B) The locations of the NSP8 
(blue spheres) and NSP9 (red spheres) binding sites on the S domain of 7SL (yellow ribbon) 
structure relative to SRP54 and SRP19 (gray) (PDB:1MFQ)(Kuglstatter et al., 2002). Right: 
Schematic of the structure and model of how NSP8/9 binding to 7SL could impact SRP protein 
binding. (C) Read enrichment across each nucleotide of 28S for NSP8 (blue) is shown. Black 
box indicates the location of the ES27 expansion sequence (28S:2889-3551 nts). Blue box 
indicates the most enriched nucleotide position on 28S rRNA (28S:3017-3529 nts). (D) The 
locations of the NSP8 (blue) and NSP9 (red) binding sites relative to the structure of SRP-
ribosome complex (PDB:3JAJ)(Voorhees and Hegde, 2015) superimposed with the structure of 
the ES27 region of 28S (Ebp1-ribosome complex; PDB:6SXO)(Wild et al., 2020). The observed 
NSP8 binding site within the ES27 region of 28S (gray) is demarcated in blue, and the NSP8 
(blue) and NSP9 (red) binding sites on 7SL (yellow) are each highlighted. Right: Schematic 
illustrating the interaction between the ribosome and SRP.  
Figure 7. NSP8 and NSP9 inhibit membrane and secretory protein trafficking. (A) 
Quantification of HEK293T cells transfected with plasmids co-expressing GFP-tagged NSPs and 
the NGFR membrane protein. Plotted is the ratio of NGFR to GFP levels for each condition. (B) 
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The ratio of puromycin-containing proteins at the cell membrane normalized to GFP expression 
for each condition. (C) Quantification of two mRNA reporters containing SL1 fused to either 
GFP (leader-GFP) or NGFR (leader-NGFR) in Vero cells infected with SARS-CoV-2 or mock 
for 24 hrs (MOI 0.1). Plotted is ratio of leader-NGFR to leader-GFP, binned by increasing 
amounts of Spike protein. (D) Density plot for leader-NGFR to leader-GFP ratios in virally 
infected Vero cells or mock treated controls. Replicate conditions were merged for display. (E) 
Model of how NSP8/9 act to suppress SRP-dependent protein trafficking upon viral infection. In 
all panels, error bars represent standard deviation across independent biological replicates, dots 
represent individual values for each replicate, * indicates p<0.05 and ** p<0.01. (F) A model of 
how SARS-CoV-2 suppresses host immune responses through multi-pronged inhibition of core 
cellular functions. Cellular mechanisms are shown in gray and viral mechanisms in red. 
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SUPPLEMENTAL FIGURE LEGENDS 
Supplemental Figure 1. Global RNA binding maps of SARS-CoV-2 proteins, Related to 
Figure 1.  (A) Protein expression gels of Halo-tagged SARS-CoV-2 proteins. Expression is 
visualized via AlexaFluor-660 conjugated Halo-ligand. (B) Example of eCLIP (top) and Halo 
(bottom) enrichments are plotted for PTBP1 over intronic regions of ITGAD mRNA. The 
location of the corresponding PTBP1 recognition motif (blue boxes) are shown. (C) Density 
scatter plot of the enrichment levels of PTBP1 over all human RNA regions as measured by 
eCLIP (x-axis) compared to the enrichment levels as measured by Halo (y-axis) for all RNAs 
identified as significantly enriched by eCLIP. (D) Cartoon illustrating protein-adduct mediated 
reverse transcriptase read stops at binding motifs (top). PTBP1 crosslink-induced truncation 
frequency relative to known PTBP1 motif (HYUUUYU, shown in red).  (E) Scatter plot of RNA 
abundance (log scale, x-axis) compared to Halo enrichment (log scale, y-axis) for the GAPDH 
protein across all 100-nucleotide windows of all annotated human RNAs (exon and introns) are 
plotted. Windows with significant enrichment are shown in red. (F) Representative tracks 
illustrating different mRNA binding patterns in Halo captures of NSP12 (red), NPS9 (blue), 
NSP15 (black), and N-protein (blue). Input tracks are presented for each mRNA (gray).  
 
Supplemental Figure 2. NSP16 binds to the U1 and U2 components of the spliceosome at 
their mRNA recognition sites, Related to Figure 2. (A) Comparison of U1 RNA enrichment 
across SARS-CoV-2 Halo capture datasets. (B) NSP16 binding traces along U1 RNA between 
two separate captures. Splice site recognition domain is highlighted in gray. (C) Comparison of 
U2 RNA enrichment across SARS-CoV-2 Halo capture datasets. (D) NSP16 binding traces 
along U2 RNA between two separate captures. Branch point recognition domain is highlighted in 
gray. (E) NSP16 immunofluorescence in Vero E6 cells infected (or mock infected) with SARS-
CoV-2 at an MOI of 0.1 for 48h. Four representative fields are displayed, with size bar indicating 
10 microns. (F) Western blot confirmation of NSP16 and NSP1 antibodies used to generate 
images in (E).  Vero cells were infected (or mock infected) with SARS-CoV-2 at an MOI of 0.1 
or 1; 72 hpi cells were lysed and probed by western blot with antibodies raised against NSP1 or 
NSP16.  (G) Imaging of HEK 293T cells transfected with Halo-tagged NSP16, NSP1, and 
NSP1∆RC plasmids. Proteins are visualized using TMR-conjugated Halo-ligand (orange) and 
counter-stained with DAPI (blue). Scale bars indicate 10 microns.  
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Supplemental Figure 3. NSP16 suppresses host mRNA splicing, Related to Figure 3. (A) 
Median of raw GFP fluorescence measured in splicing reporter assay performed in HEK293T 
cells expressing either Halo-GAPDH (gray) or Halo-NSP16 (red). Two independent biological 
replicates per condition. (B) Overview of nascent RNA-sequencing method, including 5eU 
nucleotide feeding, biotin click chemistry conjugation, and biotin-streptavidin-based iterative 
capture methods. Human/mouse mixing experimental data illustrates selective enrichment of 
labeled material over unlabeled material after three sequential captures. (C1= capture 1 
enrichment, C2= capture 2 enrichment, etc.) (C) Violin plot depicting difference in unspliced 
reads per gene (defined as the difference between number of unspliced fragment divided by total 
fragments spanning the 3’ splice site between condition and median of all control samples) for 
HEK293T cells transfected with either GAPDH (gray) or NSP16 (red) for 48hrs. All four 
individual replicates are presented. (D) Violin plot depicting difference in unspliced reads per 
gene (relative to median of GAPDH) for HEK 293T cells transfected with either GAPDH, NSP9, 
or NSP16 (red) for 48hrs. (E) Violin plot depicting difference in unspliced reads per gene 
(relative to median of the mock condition) for Calu3 cells infected with SARS-CoV-2 virus at an 
MOI of 0.01 for 48 hrs (red) or uninfected (gray). Biological replicates are presented. (F) Violin 
plot depicting fold change in total steady-state mRNA levels (mRNA initially normalized to 
ncRNA and ratio is fold normalized mock treatment) for SARS-CoV-2 infected (red) compared 
to mock infected (gray) samples. Data is presented for two biological replicates for each 
condition. (G) Normalized expression of an interferon signaling reporter upon stimulation with 
IFN-β and treatment with madrasin spliceosomal inhibitor (red) or DMSO vehicle (gray). Three 
independent biological replicates were measured for each condition. (H-I) Representative 
nascent RNA tracks from SARS-Cov-2 infected (red) and mock-treated cells (gray) along Intron 
11 and Intron 12 of interferon stimulated gene, RIG-I.  
Supplemental Figure 4. NSP1 binds to the 18S ribosomal RNA near the mRNA entry 
channel to suppress global mRNA translation in cells, Related to Figure 4. (A) Comparison 
of 18S RNA enrichment across SARS-CoV-2 Halo capture datasets. (B) The location of NSP1 
binding (orange spheres) relative to 18S binding site (cyan) upon known structure of the 80S 
ribosome (gray). (C) Predicted structure of NSP1 based on Robetta modeling. The critical C-
terminal amino acids required for binding 18S (K164 and H165) are indicated as red spheres. 
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The region of homology with SERBP1 is shown in green. The observed NSP1 binding sites on 
the 18S rRNA are demarcated in cyan on the structure of the human 40S ribosome (PDB: 6G5H; 
gray)(Ameismeier et al., 2018), relative to the mRNA path (purple; 6YAL)(Simonetti et al., 
2020),  and known clogging factors (E) SERBP1 (green; 6MTE)(Brown et al., 2018) and (F) 
Stm1 (orange; 4V88)(Ben-Shem et al., 2011b). (D) An mRNA encoding GFP was added to 
HeLa cell extracts along with different concentrations of purified NSP1 protein (x-axis). The 
amount of GFP protein measured relative to the median of replicates for a buffer only control is 
shown (y-axis). Two independent dose titrations were performed and are shown on top of each 
other. (E) Schematic illustrating puromycin tagging of newly translated proteins via the SuNSET 
method. If the level of ongoing translation is high, we expect to detect a large amount of newly 
generated proteins containing puromycin; if global translation is suppressed, we expect to 
observe a decrease in the amount of puromycin integrated into proteins. (F) Western blot of 
global puromycin incorporation into proteins of HEK293T cells transfected with either Halo-
GFP (left) or Halo-NSP1 (right).  GAPDH levels were measured in the same lysates to normalize 
for total protein in the sample (bottom). (-) puro lanes indicate transfected samples that were not 
treated with puromycin. (G) Quantification of puromycin intensity across each lane of the gel in 
Panel F. The ratio of puromycin signal over total GAPDH signal is plotted for individual 
replicates. (H) Vero E6 cells were infected (or mock infected) with SARS-CoV-2 at an MOI of 
0.01.  48hpi cells were labelled with media containing puromycin, and lysates were probed by 
western blot. (I) As a control for total protein levels, after samples in (G) were run on a SDS-
PAGE gel, transferred to nitrocellulose, and total proteins were stained with PONCEAU before 
blocking/antibody detection of puromycin signal. (J) Normalized GFP fluorescence intensity of 
GFP reporter co-transfected in HEK293T cells in the presence of the NSP1∆RC mutant that does 
not bind to 18S (gray) or NSP1 (cyan) proteins. Three independent biological replicates were 
measured for each sample. Note: This experiment was performed alongside the various controls 
displayed in Figure 4D and are plotted on the same scale. (K) mRNA levels of ISG54 and IFN-β 
following stimulation with poly(I:C) normalized to levels in unstimulated A549 cells. (L and M) 
mRNA and protein levels of IFN-β following stimulation with poly(I:C) normalized to levels in 
unstimulated A549 cells transfected with NSP1∆RC mutant (gray) or NSP1 (cyan). Two 
independent biological replicates were measured for each condition. In all panels, error bars 
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represent standard deviation across replicates, and dots represent individual values for each 
replicate. * indicates p<0.05, ** p<0.01, and *** p<0.001. 
 
Supplemental Figure 5. The 5’ viral leader sequence protects mRNAs from NSP1-mediated 
translational inhibition, Related to Figure 5. (A) A schematic of the experimental design 
containing two reporter RNAs encoding fluorescent proteins, without the viral leader (top) and 
with the viral leader sequence appended to the 5’ end of the mRNA (bottom). Viral leader 
represented by three stem-loops in red. (B) Representative images of HEK 293T cells co-
transfected with GAPDH or NSP1 along with mCherry RNA with or without SARS-CoV-2 
leader sequence. (C) Schematic illustrating the insertion of 5 nucleotides between the 5’ cap and 
the viral leader sequence. NSP1 protein represented in red. (D) Quantification of mCherry 
expression in HEK 293T cells transfected with mCherry RNAs, fused to different 5’ leader 
variants, and either GAPDH or NSP1. Values are normalized to the median values of mCherry 
levels from control condition (GAPDH with + mCherry). At least 3 independent biological 
replicates per condition. Dots represent value for each independent replicate (e.g. NSP1 -L 
contains 6 independent replicates). (E) Quantification of mCherry expression from HEK 293T 
cells transfected with Halo-tagged NSP1 WT or NSP1∆RC mutant, along with leader-mCherry 
expressing plasmids. Values are normalized to the median values of mCherry levels in control 
sample (NSP1 with + leader-mCherry). Two independent biological replicates were measured 
per condition. In all panels, error bars represent standard deviation across replicates, and dots 
represent individual values for each replicate. * indicates p<0.05 and ** p<0.01. 
 
Supplemental Figure 6. NSP8 and NSP9 bind to the 7SL RNA component of the Signal 
Recognition Particle, Related to Figure 6. (A) Comparison of 7SL RNA second read 
enrichment across viral protein capture datasets (top) with region of highest enrichment for 
NSP8/9 boxed. Independent expression, purification, and sequencing experiments for NSP8 and 
NSP9 were performed and are shown. (B) Comparison of 28S RNA enrichment across SARS-
CoV-2 Halo capture datasets (top). Replicate representative tracks of NSP8 (blue) and NSP9 
(red) on 28S rRNA are presented below. (C) Full view of 80S ribosome structure, interfaced 
with SRP (7SL RNA, yellow line), NSP9 binding sites on 7SL (red circles), and NSP8 binding 
sites on 7SL (dark blue circles) and on ES27 expansion segment on the 28S ribosomal RNA 
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(light blue line). (D) Imaging of HEK 293T cells transfected with Halo-NSP8 or Halo-NSP9 
plasmids. Proteins are visualized using TMR-conjugated Halo-ligand (orange) and counter-
stained with DAPI (blue) nuclear stain. Size bars indicate 10 microns. (E) Vero E6 cells were 
infected (or mock infected) with SARS-CoV-2 at an MOI of 0.1 for 48h, before fixing and 
staining with an antibody raised against NSP8 or NSP9.  Cells are counter-stained with DAPI. 
Size bars indicate 10 microns. (F) Western blot confirmation of NSP8 and NSP9 antibodies used 
to generate images in (E).  Vero cells were infected (or mock infected) with SARS-CoV-2 at an 
MOI of 0.1 or 1; 72 hpi cells were lysed and probed by western blot with antibodies raised 
against NSP8 or NSP9. 
 
Supplemental Figure 7. NSP8 and NSP9 inhibit membrane and secretory protein function, 
Related to Figure 7. (A) Schematic illustrating Signal Recognition Particle-mediated 
recognition and translocation of nascent membrane and secreted proteins (left). Upon SRP 
dysfunction, membrane and secreted proteins are predicted to be mislocalized and degraded 
(right). (B) Quantification of truncated Nerve Growth Factor Receptor (NGFR) fluorescence 
normalized to eGFP fluorescence (NGFR:GFP) from HEK 293T cells transfected with control 
EED plasmid together with siRNAs targeting protein components of Signal Recognition Particle, 
SRP54 and SRP19. (C) Quantification of Membrane SuNSET puromycin staining fluorescence 
normalized to eGFP fluorescence (Puromycin:GFP) from HEK 293T cells transfected with 
control EED plasmid together with with siRNAs targeting protein components of Signal 
Recognition Particle, SRP54 and SRP19. Three independent replicates for control and one 
replicate for siRNA treatments within this experiment. (D) NGFR:GFP ratio from Calu3 human 
lung epithelial cells infected with SARS-CoV-2 for 24 hrs at an MOI of 0.1. Density comparison 
between Spike positive cells in virally infected condition to Spike negative cells in virally 
infected condition. (E) Signal P analysis of open reading frames of SARS-CoV-2 expressed 
proteins utilized in study. Proteins with greater than 0.95 predicted probability indicated Signal P 
algorithm are highlighted in green. (F) Top: Signal P analysis of open reading frames of various 
immunoregulatory cytokines and proteins, including Interferon Beta and Beta-2-Microglobulin-
Precursor. Bottom: Signal P analysis of NGFR (membrane reporter) amino acid sequence and 
plot of signal peptide probability along the first 70 amino acids of NGFR sequence. In all panels, 
error bars represent standard deviation across replicates, and dots represent individual values for 
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each replicate. * indicates p<0.05 and ** p<0.01. (G) Expression of an interferon stimulated 
gene reporter upon transfection with GAPDH or NSP8 and NSP9 (in combination), followed by 
stimulation with IFN-β. We note that because this assay measures intensity across a population 
of cells, any cells that are not transfected by NSP8/9 would not show this effect and would lead 
to a smaller overall difference than might occur within individual cells. In contrast, NGFR and 
SUNSET flow cytometry measurements (B-C) represent analysis of cells expressing NSP8/9.  
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STAR METHODS 
 
RESOURCE AVAILABILITY 
Lead Contact  
Further information and requests for reagents and resources should be directed to and will be 
fulfilled by the Lead Contact, Mitchell Guttman (mguttman@caltech.edu). 
Materials Availability 
All constructs and plasmids generated in this study will be made available on request sent to the 
Lead Contact with a completed Materials Transfer Agreement. 
Data and Code Availability 
All datasets generated during this study are available at NCBI Short Read Archive: Bioproject 
PRJNA665692 (viral protein purifications) and PRJNA665581 (nascent and total RNA-Seq) 
 
Additional Supplemental Items are available from Mendeley Data at 
http://dx.doi.org/10.17632/zg7wp4xd5v.1 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell lines and culture conditions 
Cell lines used in this study. We used the following cell lines in this study: (i) HEK293T, a 
female human embryonic kidney cell line obtained from ATCC. (ii) HEK-Blue™ ISG, 
Interferon regulatory factor (IRF)-inducible Secreted Alkaline Phosphatase (SEAP) reporter 
HEK293 cells of female origin (Invivogen). (iii) A549, a male human lung epithelial cell line 
obtained from ATCC. (iii) Calu3, a male human lung epithelial cell line obtained from ATCC, 
(iv) Vero E6, a female African green monkey kidney cell line, kindly provided by J.L. Whitton 
and Michele Bouloy.  
Cell culture conditions. A549s, HEK293T cells and derivatives were cultured in complete media 
consisting of DMEM (GIBCO, Thermo Fisher Scientific) supplemented with 10% FBS 
(Seradigm Premium Grade HI FBS, VWR), 1X penicillin-streptomycin (GIBCO, Thermo Fisher 
Scientific), 1X MEM non-essential amino acids (GIBCO, Thermo Fisher Scientific), 1 mM 
sodium pyruvate (GIBCO, Thermo Fisher Scientific) and maintained at 37°C under 5% CO2. For 
maintenance, 800,000 cells were seeded into 10 mL of complete media every 3-4 days in 10 cm 
dishes. Vero E6 cells were maintained in complete DMEM (Thermo Fisher Scientific, 11965–
092) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, 16140–071), 1% 
HEPES Buffer Solution (Thermo Fisher Scientific,  15630–130), and 1% penicillin-streptomycin 
(Thermo Fisher Scientific,  15140–122). Calu3 cells were maintained in Eagles’s Minimal 
Essential Medium (ATCC) containing 10% FBS and 1% penicillin-streptomycin purchased from 
Thermo Fisher Scientific. All cell lines were maintained at 37°C under 5% CO2.  Cells were 
grown in a humidified incubator at 37ºC with 5% CO2. 
SARS-CoV-2 Viral Infection strains and conditions 
All experiments using infectious SARS-CoV-2 conducted at the UVM BSL-3 facility were 
performed under an approved Institutional Biosafety protocol. SARS-CoV-2 strain 2019-
nCoV/USA_USA WA1/2020 (WA1) was generously provided by Kenneth Plante and the World 
Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at the University of Texas 
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Medical Branch and propagated in Vero E6 cells. Viral infections were performed at the 
indicated multiplicity of infection in a low volume of normal cellular maintenance media 
containing 2% FBS for one hour at 37ºC, inoculum was removed and then overlaid in the 
respective cellular maintenance media containing 10% FBS for the indicated time periods.  
Experiments performed to visualize the location of viral NSP proteins (and associated antibody 
validation) were performed in a Containment Level 3 facility at the MRC-University of Glasgow 
Centre for Virus Research using SARS-CoV-2 strain England-02 (from Public Health England 
[now called National Institute for Health Protection], GISAID: EPI_ISL_407073) using a MOI 
of 0.1 or 1 (as indicated). 
 
METHOD DETAILS  
 
Generation of RNA binding maps 
 
Cloning of expression constructs.  SARS-CoV-2 protein constructs (with the exception of 
Nsp11) were a gift from Fritz Roth (see Table S3 for Addgene information)(Kim et al., 2020a) 
and were LR-cloned (Invitrogen Gateway Cloning, Thermo Fisher Scientific) into mammalian 
expression destination vector pCAG-Halo-TEV-DEST-V5-IRES-puroR.  Note that following LR 
cloning, proteins were not V5-tagged because all entry clones contained stop codons.  For 
NSP11, an entry clone was generated by BP cloning (Invitrogen Gateway Cloning, Thermo 
Fisher Scientific) a PCR amplicon (primers: 
ggGGACAAGTTTGTACAAAAAAGCAGGCTTTtcagctgatgcacaatcgtttttaaacgg and 
gGGGACCACTTTGTACAAGAAAGCTGGGTTttacaccgcaaacccgtttaaaaacgattg; template: 
pGBW-m4133457 a gift from Ginkgo Bioworks) into pDONR221. 
Expression and lysis.  For each viral protein capture, we transfected 10 µg of these expression 
vectors into HEK293T cells grown on a 15cm dish using BioT transfection reagent (Bioland) 
according to manufacturer’s recommendations. 24-48 hours post-transfection, cells were washed 
once with PBS and then crosslinked on ice using 0.25 J cm−2 (UV2.5k) of UV at 254 nm in a 
Spectrolinker UV Crosslinker. Cells were then scraped from culture dishes, washed once with 
PBS, pelleted by centrifugation at 1,000× g for 5 min, and flash-frozen in liquid nitrogen for 
storage at –80°C. We lysed batches of 5 million cells by completely resuspending frozen cell 
pellets in 1 mL of ice cold lysis buffer (50 mM Hepes, pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% 
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SDS, 0.5% Sodium Deoxycholate) supplemented with 1X Protease Inhibitor Cocktail (Promega), 
200 U of Ribolock (Thermo Fisher Scientific), 20 U Turbo DNase (Ambion), and 1X 
Manganese/Calcium Mix (0.5mM CaCl2, 2.5 mM MnCl2). Samples were incubated on ice for 10 
minutes to allow lysis to proceed. The lysates were then incubated at 37°C for 10 minutes at 700 
rpm shaking on a Thermomixer (Eppendorf). Lysates were cleared by centrifugation at 15,000× 
g for 2 minutes. The supernatant was collected and kept on ice until bound to the HaloLink Resin 
(Promega).  Of the 1mL lysis volume, 50uL was set aside for input, 20uL used for protein 
expression confirmation, and the rest for capture on HaloLink Resin as described below. 
Expression confirmation. Lysis supernatant set aside for expression testing was combined with 
1.5µl of 1:60 diluted HaloTag® Alexa Fluor® 660 Ligand (Promega) and incubated at room 
temperature for 20 min in the dark.  To stop the reaction, we added LDS loading buffer to 1X 
final concentration (4µL 10X Bolt reducing agent, 10µL 4X NuPAGE® LDS Sample Buffer, 
4µL H2O), denatured the mixture at 90°C for 10 min and ran on a Bolt™ 4-12% Bis-Tris Plus 
Gel (all products Thermo Fisher Scientific).   Resolved gel was imaged directly on a Licor 
Odyssey CLx. 
Protein capture. We used 200 µL of 25% HaloLink Resin slurry (50 µL of HaloLink Resin total) 
per 5 million cells. Resin was washed three times with 2 mL of 1X PBS-T (1x PBS + 0.1% 
Triton X-100) and incubated in 1X Blocking Buffer (50 mM HEPES, pH 7.4, 100 µg/mL BSA) 
for 20 minutes at room temperature with continuous rotation. After the incubation, resin was 
washed three times with 1X PBS-T. The cleared lysate was mixed with 50µl of HaloLink Resin 
and incubated at 4 °C for 3-16 hrs with continuous rotation. The captured protein bound to resin 
was washed three times with lysis buffer at room temperature and then washed three times at 
90°C for 3 minutes while shaking on a Thermomixer at 1200 rpm with each of the following 
buffers: 1X NLS buffer (1xPBS, 2% NLS, 10 mM EDTA), High Salt Buffer (50 mM HEPES, 
pH 7.4, 0.1% NP-40, 1M NaCl), 8M Urea Buffer (50 mM HEPES, pH 7.5, 0.1% NP-40, 8 M 
Urea), Tween buffer (50 mM HEPES, pH 7.4, 0.1% Tween 20) and TEV buffer (50 mM HEPES, 
pH 7.4, 1 mM EDTA, 0.1% NP-40). The extended incubation of the bound RNA with the wash 
buffers leads to chemical fragmentation of the RNA yielding sizes that are suitable for RNA 
library preparation and binding site resolution. Between each wash, samples were centrifuged at 
1,000× g for 30 seconds and supernatant was removed.  After the last wash, samples were 
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centrifuged at 7,500× g for 30 seconds and supernatant was discarded.  For elution, the resin was 
resuspended in 100 µL of NLS Buffer and 10 µL of Proteinase K (NEB) and the sample was 
incubated at 50°C for 30 minutes while shaking at 1200 rpm.  Input samples were similarly 
digested.  Capture reactions were transferred to microspin cups (Pierce, Thermo Fisher 
Scientific), centrifuged at 2,000× g for 30 seconds, and elutions used for RNA purification by 
RNA Clean and Concentrate-5 kits (Zymo, >17nt protocol). 
For qPCR analysis, cDNA was generated from purified RNA using Maxima H- reverse 
transcriptase (Thermo Fisher Scientific) following manufacturer’s recommendations. 
Amplification reactions were assembled with primer sets indicated in Table S2 and 
LightCycler® 480 SYBR Green I Master (Roche) following manufacturer’s protocols and read 
out in a Roche Lightcycler 480. 
Library construction.  RNA-Seq libraries were constructed from purified RNA as previously 
described(Van Nostrand et al., 2016). Briefly, after proteinase K elution, the RNA was 
dephosphorylated (Fast AP) and cyclic phosphates removed (T4 PNK) and then cleaned using 
Silane beads as previously described(Van Nostrand et al., 2016). An RNA adapter containing a 
RT primer binding site was ligated to the 3’ end of the cleaned and end-repaired RNA. The 
ligated RNA was reverse transcribed (RT) into cDNA, the RNA was degraded using NaOH, and 
a second adapter was ligated to the single stranded cDNA. Library preparation was the same for 
input samples except that an initial chemical fragmentation step (90°C for 2 min 30 s in 1X 
FastAP buffer) was included prior to FastAP treatment. This chemical fragmentation step was 
designed to be similar to the fragmentation conditions used for purified Halo bound samples. The 
DNA was amplified and Illumina sequencing adaptors were added by PCR using primers that are 
complementary to the 3’ and 5’ adapters. The molarity of PCR amplified libraries were measured 
by Agilent Tapestation High Sensitivity DNA screentapes and all samples were pooled at equal 
molarity. The pool was then purified and size selected on a 2% agarose gel and cut between 150-
700 nts. The final libraries were measured by Agilent Bioanalyzer and Qubit high sensitivity 
DNA to determine the loading density of the final pooled sample. Pooled samples were paired-
end sequenced on an Illumina HiSeq 2500 with read length 35 x 35nts. 
Antibody Generation 
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To generate the sheep polyclonal anti-NSP1, anti-NSP8, anti-NSP9, and anti-NSP16 antibodies 
utilized in this study, NSP1, NSP8, NSP9 and NSP16 (using QHD43415.1 as reference) were 
cloned into pGex (GST-tagged) and pMex (MBP-tagged), in order to produce GST- and MBP-
tagged respective NSP proteins.  The N-terminal GST fusions were then used as antigens to 
immunize sheep.  A bleed from the sheep was taken 7 days later, after which the MBP-tagged 
NSP proteins were used for serum affinity purification of the antibodies.  To validate expression 
of the antibodies, Vero E6 cells were uninfected (mock) or infected with SARS-CoV-2 England-
02 using a MOI of 0.1 or 1 (as indicated).  At 72 hours post infection, the samples were 
harvested and the resulting whole cell lysates were probed by western blot with either sheep anti-
NSP or mouse anti-actin (Developmental Studies Hybridoma Bank JLA20, antibody registry ID: 
AB_528068) primary antibodies.  
 
Microscopy imaging 
Cells were seeded on gelatin/laminin and poly-D-lysine (Sigma) coated coverslips or chamber 
slides (Nunc, Thermo Fisher Scientific) and transfected with mammalian expression vectors for 
Halo-tagged viral proteins.  After 16-24 hours, cells were incubated with TMR-HaloTag® 
Ligand (Promega) according to manufacturer’s instructions, washed with PBS and fixed in 4% 
Formaldehyde (Pierce, Thermo Fisher Scientific).  Cells were subsequently incubated in DAPI 
for 10 min and washed with PBS.  For chamber slides, samples were imaged directly.  For 
coverslips, samples were washed with water and mounted with ProLong Gold + DAPI 
(Molecular Probes, Thermo Fisher Scientific).  We acquired images on a Nikon TS100-F 
widefield microscope or a Zeiss LSM800 inverted confocal microscope, collecting in line-
scanning mode with 4x line averaging using a 63x oil objective. 
For staining of infected cells, cells were fixed and permeabilized in 8% formaldehyde 1% Triton, 
and subsequently labelled with primary antibodies raised in sheep to SARS-CoV-2 at 1/500 
dilution, followed by incubation with a rabbit anti-sheep Alexa 555 secondary antibody (Abcam, 
ab150182) at 1/1000 dilution and mounted with DAPI in the medium (Thermo Fisher Scientific, 
cat# P36395). Cells were imaged with a Zeiss LSM 880 confocal microscope, with 1 Airy unit 
pinhole for all primary antibody channel acquisitions and pixel size 0.07 µm x 0.07 µm. The 
objective lens used was a Zeiss Plan-Apochromatic 63x/1.4NA M27.  
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Structure modeling 
NSP1 homology model. The predicted model of SARS-CoV-2 NSP1 was generated using the 
transform-restrained Rosetta (trRosetta) algorithm, a deep learning-based modeling method 
based on the Rosetta energy minimization pipeline with additional distance and interaction 
restraints generated from co-evolution(Yang et al., 2020). All figures were generated using 
Pymol (www.pymol.org). 
 
NSP1-ribosome model. The model of NSP1 bound to the ribosome was generated using 
Modeller version 9.24(Webb and Sali, 2016). The C-terminal sequence of NSP1 
(KHSSGVTRELMRELNGG) was modeled using the structure of SERBP1 bound to the 
ribosome (PDB ID: 6MTE, chain w) as a template. The default Modeller parameters were used 
to create an alignment of NSP1 and SERBP1 and to generate the model, and all atoms within 6Å 
of SERBP1 were included in the model to define the neighboring environment. Twenty models 
were generated and the model with the lowest DOPE score was selected to visualize with 
Pymol(Delano, 2002). 
Structural analysis of protein-RNA interactions. X-ray crystal structures and cryo-electron 
microscopy structures were obtained from the Protein Data Bank (www.rcsb.org)(Berman et al., 
2000) and visualized with PyMOL(Delano, 2002). For U1 and U2 structural analysis, we used a 
cryo-EM structure of the pre-catalytic human spliceosome (PDB ID: 6QX9). For 7SL structural 
analysis, we used an X-ray crystal structure of the human signal recognition particle (PDB ID: 
1MFQ). To examine human SRP in the context of the ribosome, we used a cryo-EM structure of 
the mammalian SRP-ribosome complex (PDB ID: 3JAJ). To analyze the ribosomal ES27 
expansion segment, we superimposed a cryo-EM structure of the expansion segment (PDB ID: 
6SXO) onto the complete ribosome structure (PDB ID: 3JAJ) using the PyMOL command 
“super.” Finally, for NSP1–18S rRNA structural analysis, we used multiple structures of the 
ribosome, including structures of the pre-40S subunit (PDB ID: 6G5H), 48S late-stage initiation 
complex (PDB ID: 6YAL), 80S in complex with SERBP1 (PDB ID: 6MTE), and 80S in 
complex with Stm1 (PDB ID: 4V88). 
Recombinant NSP1 production 
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NSP1 was cloned into a bacterial expression vector resulting in N-terminally tagged Halo-6xHis-
tagged Nsp1.  The NSP1 sequence was PCR amplified from Addgene Nsp1 entry vector to add a 
N-terminal 6X HIS tag and restriction enzyme sites for digestion and ligation into N-terminal 
Halo bacterial expression vector. This construct was transformed into BL21 DE3 E. coli 
(Agilent), expanded to a 500mL liquid culture, and grown until OD600 reached 1.0.  IPTG was 
added to a final concentration of 1mM.  After 3 hours of IPTG induction, bacteria was 
centrifuged for 15 min at 5000× g.  Pellet was lysed with binding buffer (50mM HEPES, pH 7.5, 
20mM MgCl2, 600mM NaCl, 2mM TCEP, 10mM Imidazole, 2mM ATP, 1% Triton X-100) 
supplemented with ATP (2mM), protease inhibitor cocktail (Promega), Benzonase (Sigma) and 
Triton-X 100 (Sigma) using 5mL of lysis mix per gram of wet cell paste.  Cell suspension was 
rocked for 20 min at room temperature and then centrifuged at 16,000× g for 20 min at 4°C.  
Supernatant was incubated with washed iMAC resin (Bio-Rad) and rocked for 20 min at room 
temperature.  We loaded the resin-lysate mixture into an appropriately-sized column and washed 
with 5 column volumes of binding buffer (50mM HEPES, pH 7.5, 20mM MgCl2, 600mM NaCl, 
2mM TCEP, 10mM Imidazole, 2mM ATP, 1% Triton X-100) followed by 10 column volumes 
of wash buffer (50mM HEPES, pH 7.5, 600mM NaCl, 2mM TCEP, 20mM Imidazole, pH 8).  
Recombinant NSP1 (rNSP1) was eluted with 5 column volumes of elution buffer by adding 1 
column volume at a time with column flow stopped, collecting eluate after each addition, and 
waiting 15 min between each elution buffer addition.  We dialyzed these eluates with a 10mL 
Spectra-Por® Float-A-Lyzer® G2 (Spectrum Laboratories) into storage buffer (50mM HEPES, 
pH 7.5, 150mM NaCl, 10% glycerol) at 4°C using 2 exchanges, one after 2 hours and then 
overnight. 
In vitro translation assays 
Pierce 1-Step Human Coupled IVT-DNA (Thermo Fisher Scientific) in vitro translation kit was 
used to measure rNsp1-dependent translation inhibition. Bovine Serum Albumin (BSA), and 
buffer only controls were used to control for the addition of excess protein or changes in buffer 
composition. To measure translation inhibition, 5µL in vitro translation reactions were 
assembled, scaled according to manufacturer’s recommendations. The included control plasmid 
pCFE-GFP was used to measure translational output of the reactions. GFP fluorescence was 
measured on a BioTek Cytation3 plate reader using emission filters for GFP fluorescence. 1.5µM 
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stock dilutions of rNsp1 and BSA were made in storage buffer (50mM HEPES, pH 7.5.,150mM 
NaCl,10% glycerol). Subsequent 10 fold dilutions were made in storage buffer to span a 
concentration range of 1000 nM to 1 nM for each protein in the final reaction. 10 µL of the 
diluted protein solution was added to the 5µL translation reactions, and incubated for 5 minutes 
at room temperature prior to the addition of the GFP reporter plasmid. Duplicate reactions were 
made to measure variability for each condition. In addition, a buffer only control was included to 
measure the effect of dilution of the translation reaction by the storage buffer. After the 5 minute 
incubation, 50 ng of GFP reporter plasmid was added to each reaction and incubated at 30°C for 
4 hours prior to fluorescence detection. Two microliters from each reaction was measured in 
duplicate on a Biotek Cytation3 microplate reader using excitation and emission filters for GFP.  
Sample readings were blanked by subtracting values obtained from the buffer only control. 
Promega’s Rabbit Reticulocyte Lysate System was also used to assay translation inhibition.  To 
measure translation inhibition, 10µL in vitro translation reactions were assembled, scaled 
according to manufacturer’s recommendations.  For each translation reaction, either 10µL of 
recombinant protein storage buffer or rNSP1 was added, followed by 500ng of mRNA.  After 4 
hours of incubation at 30°C, luciferase was read out using the Bright-Glo luciferase assay 
(Promega) or GFP fluorescence was measured, both on a Biotek Cytation3 plate reader. 
In vivo translation assays 
We assayed translation in HEK293T cells transfected with mammalian expression vectors, 
mRNAs, or combinations of these.  For mRNA transfections of fluorescence protein translation 
reporters (including unmodified, +SARS-CoV2 leader sequence, +SL1, +SL2-SL1, and +5nts), 
DNA templates for in vitro transcription were generated with sequences appended to the 5’ end 
of GFP and mCherry (see Tables S4 and S5 for primers and templates, respectively) and 
transcribed using HiScribe™ T7 ARCA mRNA Kit with tailing (New England Biolabs).  For 
Nsp1 mRNA transfection, indicated primers from Table S4 were used to add restriction enzyme 
sites for cloning into pT7CFE1-CHis backbone provided in the Pierce Human 1-step Coupled 
IVT Kit and HiScribe™ T7 High Yield RNA Synthesis Kit (New England Biolabs) was used for 
in vitro transcription.   
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Using BioT transfection reagent, mammalian expression vectors for a GFP reporter and for 
SARS-CoV-2 viral proteins were transfected into HEK293T cells seeded for imaging, as 
described above, or seeded in 24 well plate format.  To transfect only mRNA, Lipofectamine 
messengerMax (Invitrogen, Thermo Fisher Scientific) or TransIT-mRNA Transfection Kit 
(Mirus Bio) was used.  For transfections that included both mRNA and plasmid, Lipofectamine 
2000 (Invitrogen, Thermo Fisher Scientific) was used.   
To measure fluorescence at 24 (leader-mCherry, no leader-GFP) or 48 hours (leader GFP, no-
leader mCherry) post-transfection, cells were trypsinized and processed for flow cytometry or 
transferred into black 96 well plates (Nunc) for fluorescence detection on a Biotek Cytation 3 
plate reader. For flow cytometry, lifted cells were washed with CBH buffer (10mM HEPES, pH 
7.4, 0.5% BSA, Hank’s Balanced Salt Solution (GIBCO, Thermo Fisher Scientific)), 
resuspended with a viability dye (7-AAD or DAPI) and analyzed on a MACSQuant Vyb.  
Acquistion files were analyzed with FlowJo analysis software. 
SUnSET assay 
To assay global protein translation, a SUnSET assay was performed as previously described 
(Schmidt et al., 2009). Mammalian expression vectors were exchanged for versions that did not 
confer puromycin resistance and thus, for these experiments, LR reactions were carried out with 
destination vector pB-Halo-DEST-IRES-NGFR.   Resulting expression vectors drive protein 
expression by a dox-inducible promoter, contain the rtTA needed for dox induction, and produce 
an N-terminally-tagged Halo fusion protein.  Generation of this destination vector made use of 
the pB-TAG-ERN backbone (a gift from Knut Woltjen; Addgene plasmid # 80476; 
http://n2t.net/addgene:80476 ; RRID:Addgene_80476)(Kim et al., 2016) and the NGFR 
(Truncated Human Nerve Growth Factor Receptor) coding sequence from Addgene plasmid 
#27489 (a gift from Warren Pear; http://n2t.net/addgene:27489 ; RRID:Addgene_27489)(Izon et 
al., 2001b). 
We transfected these mammalian expression vectors for NSP1 and GFP into HEK293T using 
BioT transfection reagent. After 3 hours, doxycycline (Sigma) was added to a final concentration 
of 2µg/mL.  After 24 hours, cells were incubated with puromycin (10µg/mL) for 10 min, then 
washed with fresh media, and harvested with cold PBS.  Pelleted cells were lysed for 10 min on 
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ice (mixing after 5 min) with 100uL RIPA buffer supplemented with protease inhibitor cocktail 
(Promega).  Insoluble debris was pelleted by centrifuging at 12,500 × g for 2.5 minutes and 
supernatant was run on a Bolt™ 4-12% Bis-Tris Plus Gel (Thermo Fisher Scientific).  Proteins 
were then transferred to nitrocellulose using the iBlot transfer system (Thermo Fisher Scientific) 
and Western blotting carried out using an anti-puro antibody (clone 12D10, EMD Millipore). 
SUnSET in SARS-CoV-2 infected cells 
SUnSET in SARS-CoV-2 infection was performed as above with the following modifications.  
Cells were infected or not (mock) with SARS-CoV-2, and 48 hpi cells were incubated with 
puromycin (10µg/mL) for 20 min.  Media was aspirated and cells lysed directly in 2X Laemmli’s 
buffer (Biorad), heated at 95ºC for ten minutes and run on a 4-12% NuPAGE Gel (Thermo 
Fisher Scientific).  Proteins were transferred to nitrocellulose using the iBlot transfer system and 
probed as above. 
Membrane protein reporter experiments 
To assay SRP-dependent membrane protein transport to the cell surface, we monitored surface 
arrival of exogenously expressed Neuronal Growth Factor Receptor (NGFR) by flow cytometry 
in the presence of NSPs.  Mammalian expression vectors were exchanged for versions that 
contained an IRES-NGFR to co-express a membrane reporter and thus, for these experiments, 
LR reactions were carried out with destination vector pB-6xHis-GFP-DEST-IRES-NGFR.   
Resulting expression vectors drive protein expression by a dox-inducible promoter, contain the 
rtTA needed for dox induction, and produce an N-terminally-tagged His-GFP fusion protein and 
a co-expressed NGFR.  The GFP here is an enhanced GFP containing an amino acid substitution 
(A205K) to generate a monomeric variant based on previous literature(Alberti et al., 2018).  
We transfected these mammalian expression vectors for NSP8, NSP9, NSP1∆RC mutant and 
EED into HEK293T using BioT transfection reagent, induced expression with 2µg/ml 
doxycycline 24 hours after transfection, and assessed surface arrival of NGFR 24 hours after 
induction.  To carry out flow cytometric analysis, cells were lifted with 1mM EDTA, washed 
once with PBS and stained with PE-labeled anti-NGFR antibody (Biolegend; 1/600 dilution in 
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PBS, 0.5%BSA) and analyzed on a MACSQuant Vyb.  Fluorescence intensity measurements 
were taken for GFP and PE and analyzed using FloJo analysis software. 
siRNA experiments for SRP19 and SRP54 
To knockdown SRP19 and SRP54, siRNAs targeting each (Dharmacon cat# L-019729-01-0005 
and L-005122-01-0005, respectively) were transfected into HEK293T cells using Lipofectamine 
RNAiMAX (Invitrogen) according to manufacturer’s protocols.  To validate knockdown, 
transfected cells were assayed by qPCR using primer sets (Table S2) to amplify each target as 
well as normalizer Calm3.  Transfections were carried out 48 hours prior to assaying cells, either 
by qPCR, membrane reporter, or membrane SUnSET (see below) experiments. 
Leader-NGFR measurements 
Calu3 and Vero cells were transfected with mRNAs encoding leader-NGFR and leader-GFP 
using TransIT-mRNA Transfection Kit (Mirus) and subsequently infected with SARS-CoV-2 at 
an MOI of 0.1. After 24 hours, cells were washed with PBS, trypsinized and fixed in 4% PFA for 
20 minutes before staining with biotinylated anti-NGFR (BioLegend) and anti-SARS-Cov-2 
Spike Antibody (Sino) and subsequently stained with PE-labeled anti-Rabbit (Thermo, P-
2771MP) and PacBlue-labeled streptavidin (Thermo, S1222). FACS was performed on a 
MACSquant Flow cytometer and analyzed using FloJo analysis software; FACS distributions 
were compared using a 2-tailed Kolmogorov-Smirnov test. For these experiments, RNA was 
transcribed from a PCR template (see Table S4) using the HiScribe T7 ARCA mRNA kit (with 
tailing).  
Membrane SUnSET assay 
To assay transport to the cell surface of all plasma membrane proteins, the SUnSET assay was 
adapted to puro-label surface proteins as previously described (Schmidt et al., 2009), and read 
out by flow cytometry.  Briefly, cells were incubated with puromycin as described above, 
followed by two quick washes and a chase with fresh complete media for 50 min.  Cells were 
lifted with 1mM EDTA as described above and stained with an anti-puro antibody (clone 12D10, 
EMD Millipore) conjugated to Alexa-647.  For these experiments, NSP was expressed from the 
same vector described above for membrane reporter assays. Fluorescence intensity 
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measurements were taken for GFP and Alexa-647 on a MACSquant Flow cytometer and 
analyzed using FloJo analysis software; distributions were compared using a 2-tailed Kolmogov-
Smirnov. 
 
Splicing assessment experiments 
IRF7-GFP splicing reporter 
To assess splicing efficiency, exons 5-6 of mouse IRF7 (ENMUST00000026571.10) containing 
its endogenous intron were fused upstream of 2A self-cleaving peptide and eGFP and cloned into 
an MSCV vector (PIG, Addgene)(Mayr and Bartel, 2009). This construct was co-transfected into 
HEK293Ts with NSP16 or GFP and measured 24 hours after transfection by flow cytometry 
(Macsquant) and analyzed using FloJo analysis software. 
5EU labeling of RNA 
SARS-Cov2 or mock infected Calu3 cells and Nsp16- or GAPDH-expressing HEK293Ts were 
labeled with 5-Ethynyl-uridine (5EU; Jena Bioscience) by adding 5EU containing media to cells 
for 20 min at a final concentration of 1mM, as previously described(Jao and Salic, 2008).  After 
the pulse label, cells were washed with warm PBS and lysed in RLT buffer (Qiagen).  Total 
RNA was isolated from cells using manufacturer’s protocols for Qiashredder and RNeasy RNA 
isolation (both Qiagen), followed by Turbo DNase treatment (Ambion, Thermo Scientific), and 
Zymo RNA Clean and Concentrate.  For each sample, 2µg of RNA was used for ligation of a 
unique barcoded RNA adaptor, following the relevant steps in the protocol described above in 
Library Construction of RNA-seq libraries.  Samples were then pooled before proceeding to 
biotinylation steps. 
Biotinylation of 5EU labeled RNA 
To biotinylate 5EU-labeled RNA, samples were first mixed, in order, with water, HEPES (100 
mM), biotin picolyl azide (1 mM; Click Chemistry Tools) and Ribolock RNase inhibitor, then 
added to premixed CuSO4 (2 mM) and THPTA (10mM), and finally added to freshly prepared 
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sodium ascorbate (12mM), as previously described(Hong et al., 2009).  The click reaction was 
incubated for 1 hour at 25ºC with 1000rpm shaking on an Eppendorf thermomixer followed by 
RNA purification using >17nt protocol for Zymo Clean and Concentrate. 
Sequential capture of biotinylated RNA 
We completed three rounds of sequential capture on streptavidin beads to isolate nascent 
transcripts (see Figure S3B).  To capture biotinylated RNA, MyOne Streptavidin C1 Dynabeads 
(ThermoFisher Scientific) were first washed three times in Urea buffer (10mM HEPES, pH 7.5, 
10mM EDTA, 0.5M LiCl, 0.5% Triton X-100, 0.2% SDS, 0.1% sodium deoxycholate, 2.5mM 
TCEP, 4M Urea) followed by three additional washes in M2 buffer (20mM Tris, pH 7.5, 50mM 
NaCl, 0.2% Triton X-100, 0.2% sodium deoxycholate, 0.2% NP-40).  Washed beads were mixed 
with 3 parts 4M Urea buffer and 1 part biotinylated RNA and incubated for 60 min with 900rpm 
thermomixer shaking at room temperature.   
After magnetic separation, beads were washed 3 times with M2 buffer followed by 3 washes 
with Urea buffer at 37 ºC at 750rpm for 5 min.  RNA was eluted from beads in 2 sequential 
elutions by incubating with elution buffer (5.7M guanidine thiocyanate , 1% N-lauroylsarcosine; 
both Sigma) at 65 ºC for 2 minutes, repeating with more elution buffer for a second elution. 
The elutions were pooled, diluted with Urea buffer, incubated with pre-washed streptavidin 
beads, washed, and eluted for 2 additional rounds exactly as described above for a total of 3 
sequential captures.   
Final elutions were pooled, cleaned with Zymo RNA Clean and Concentrate following 
manufacturer’s protocols, and carried through RNA-seq library preparation as described above 
starting with the reverse transcription step. 
 
Interferon stimulation experiments  
HEK-Blue™ ISG cells were seeded in 96 well plates, transfected with Nsp1 mammalian 
expression vectors using BioT and stimulated with 50 ng/ml human IFN-B (R&D Systems). 
Supernatants were assayed for alkaline phosphatase as per manufacturer instructions using 
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QUANTI-Blue reagent (Invivogen).  
 
HEK-293T cells were seeded in 6 well plates, transfected with either Halo-tagged GapdH, Nsp1, 
NSP8 and NSP9 in combination, or NSP16 mammalian expression vectors using BioT. 24 hours 
later, the media was replaced with media containing 50 ng/ml human IFN-β (R&D Systems). 
Expression was assayed using live cell Halo-imaging. Halo-TMR ligand was diluted 1:200 in 
media and added to the culture for a 1:1000 final dilution. Samples were incubated 30 minutes at 
37°C, 5% CO2 and then the media was aspirated. Wells were rinsed twice with PBS, then media 
was added back to the wells. Samples were incubated 30 minutes at 37°C, 5% CO2 to allow 
uncoupled ligand to diffuse out of the cells. Media was then aspirated and replaced, and cells 
were imaged by widefield fluorescence microscopy. Cultures were ultimately harvested for RNA 
24 hours later, or 48 hours post transfection. 
A549s were seeded in 6 well plates, transfected with NSP1 mammalian expression vectors using 
Lipofectamine 2000 and stimulated with 1 µg/ml HMW poly(I:C) (Invivogen) 24h after 
transfection.   Supernatant was assayed for secreted IFN-β by ELISA (Human IFN Beta ELISA, 
High Sensitivity, PBL) 24 hours after stimulation, and RNA from cells was purified and assessed 
for ISG gene expression as normalized to GAPDH expression (SYBR Green Master Mix, Bio-
Rad).  Primers used for qPCR are listed in Table S2. 
5’ viral leader experiments 
Sars-CoV-2 Leader sequence was appended to the 5’ end of GFP and mCherry reporter 
templates via PCR. PCR templates were then transcribed using HiScribe T7 ARCA mRNA kit 
(with tailing). Leader mutants, including SL1 only, SL1/SL2 swap, and +5nts mutants were 
likewise appended to the 5’ end of fluorescent reporter templates via PCR and transcribed using 
Hiscribe T7 ARCA kit. mRNA reporters were transfected in HEK-293T cells with 
Lipofectamine MessengerMax. To measure fluorescence of mCherry and GFP reporters, 24 
hours post transfection cells were either lifted with PBS and transferred into black 96 well plates 
for fluorescence readout on a Biotek Cytation 3 or trypsinized and processed for flow cytometry.  
Alignments and phylogeny reconstructions 
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Alignments were performed with MAFFTT (v7.407) using a local alignment (linsi --ep 0.123 --
reorder [in.fasta] > [out.aln.fasta]). Resulting alignments were visualized with Geneious. 
Pairwise distance matrices were visualized with Morpheus. Phylogeny reconstructions were 
performed with IQTREE multicore (v1.6.12), model selection with 1000 bootstrap 
pseudoreplicates (iqtree -s [out.aln.fasta] -m TEST -bb 1000 -nt 4 -o [outgroup]).  Phylogenies 
were visualized with FigTree. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
Analysis of SARS-CoV-2 viral protein binding to RNA 
 
Sequence alignment and analysis. For Halo purifications and RNA binding mapping sequencing 
reads were aligned to a combined genome reference containing the sequences of structural RNAs 
(ribosomal RNAs, snRNAs, snoRNAs, 45S pre-rRNA) and annotated mRNAs (RefSeq hg38) 
using Bowtie2. To distinguish between the nascent pre-ribosomal RNA and mature 18S, 28S, 
and 5.8S rRNA, we separated each of the components of the 45S into separate sequence units for 
alignment (e.g. ITS, ETS). We excluded all low quality alignments (MAPQ < 2) from the 
analysis. For mRNA analysis, we removed PCR duplicates using the Picard MarkDuplicates 
function (https://broadinstitute.github.io/picard/). 
For each RNA, we enumerated 100 nucleotide windows across the entire RNA. For each 
window, we calculated the enrichment by computing the number of reads overlapping the 
window in the protein elution sample divided by the total number of reads within the protein 
elution sample. We normalized this ratio by the number of reads in the input sample divided by 
the total number of reads in the input sample. Because all windows overlapping a gene should 
have the same expression level in the input sample (which represents RNA expression), we 
estimated the number of reads in the input as the maximum of either (i) the number of reads over 
the window or (ii) the median read count over all windows within the gene. This approach 
provides a conservative estimation of enrichment because it prevents windows from being scored 
as enriched if the input values over a given window are artificially low, while at the same time 
accounting for any non-random issues that lead to increases in read counts over a given window 
(e.g. fragmentation biases or alignment artifacts leading to non-random assignment or pileups).  
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We calculated a multiple testing corrected p-value using a scan statistic, as previously 
described(Guttman et al., 2009, 2010). Briefly, n was defined as the number of reads in the 
protein elution plus the number of reads in the control sample. p was defined as the total number 
of reads in the protein elution sample divided by the sum of the protein elution sample total reads 
and total reads in the control sample. w was the size of the window used for the analysis (100 
nucleotides). The scan statistic p-value was defined using the Poisson estimations based on 
standard distributions previously described(Naus, 1982).  
Because RNA within input samples are fragmented differently than the protein elution samples, 
we noticed that the overall positional distribution of protein elution samples was distinct from 
Input distributions. Accordingly, we used the remaining protein elution samples (rather than 
Input) as controls for each protein. Specifically, this enabled us to test whether a given protein is 
enriched within a given window relative to all other viral and control proteins. Enrichments were 
computed as described above. These values are plotted in Figure 1 and Table 1. 
Plotting and visualization. Enrichment plots for specific RNAs were visualized in 
IGV(Robinson et al., 2011) and were generated by either: (i) computing the enrichment for each 
nucleotide as described above. In this case, the read count for each nucleotide was computed as 
the total number of reads that overlapped the nucleotide. (ii) Counting the number of RT stop 
sites at a given nucleotide. In this case, we compute the alignment start position of the second in 
pair read and computed a count of each nucleotide. We normalized this count by the total 
number of reads in the sample to account for sequencing depth generated. We then normalized 
this ratio by the same ratio computed for the control sample (merge of all other protein samples) 
for each nucleotide. 
Heatmaps were generated using Morpheus (https://software.broadinstitute.org/morpheus/). All 
values were included if they contained a significant 100nt window with a p-value<0.001 (see 
above) and minimum enrichment of 3-fold above the control sample.  
Gene ontology analysis. The 66 non-N enriched mRNAs were analyzed against the Gene 
Ontology Biological Processes and Reactome gene sets using the Molecular Signatures Database 
(MSigDB)(Liberzon et al., 2015). Significantly enriched gene sets with an FDR<0.05 were used. 
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To ensure that significant gene sets were not being driven by the multiple ribosomal proteins or 
histone proteins, these analyses were also carried out excluding these proteins.  
 
 
Splicing analysis of 5EU data 
Sequenced reads were demultiplexed according to barcoded RNA adaptor sequences ligated to 
each respective sample. Trimmomatic (https://github.com/timflutre/trimmomatic ) was used to 
remove any contaminating Illumina primer sequences in the reads and low quality reads. 
Demultiplexed and trimmed files were then aligned to a hg19 reference genome using the splice-
aware STAR aligner (https://github.com/alexdobin/STAR). Alignments were then deduplicated 
for PCR duplicates using PICARD MarkDuplicates (https://broadinstitute.github.io/picard/). 
Aligned read-fragments were defined as read1 and read2 contained within a paired-end read 
fragment along with the insert between these two reads. We defined a set of high-quality 
represented isoforms per gene using the APPRIS database(Rodriguez et al., 2013). All read-
fragments that spanned any 3’ splice site within an isoform of one of these genes was retained. 
For each 3’ splice site spanning fragment, we classified the read-fragment as a spliced fragment 
if it spanned an exon-exon junction (e.g. aligned entirely within 2 distinct exons) or an unspliced 
fragment if it spanned an intron-exon junction (e.g. one of the reads was contained -or partially 
contained – within the intron). For each isoform, we computed an unspliced ratio by counting the 
total number of reads that were classified as unspliced divided by the total number of read-
fragments spanning 3’ splice sites within that gene. To ensure that the splicing ratio that we 
measured is a reliable metric and not inflated/deflated due to low read counts, we only included 
genes that contained at least 10 read-fragments in each sample and where the total number of 
reads in the control and sample conditions (when merged together) contained a significant 
number of reads to reliably measure a difference between the two groups as measured by a 
hypergeometric test (p<0.01).  
Because different genes contain different baseline splicing ratios due to gene length and 
coverage, we computed a change in the splicing ratio for each gene independently. To do this, 
we subtracted the unspliced ratio for each sample from the average unspliced ratio for that gene 
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in all of the control samples. We plotted the overall distribution of these differences in splicing 
ratios as violin plots for each sample. If there is no change in splicing ratio, we would expect that 
some genes would have higher splicing ratios and others lower splicing ratios but that the overall 
distribution would be centered around 0. 
 
Analysis of total RNA in SARS-CoV-2 infected samples 
Total RNA-Seq libraries were generated from the same mock infected and SARS-CoV-2 virally 
infected Calu3 samples treated with 5EU. Prior to 5EU purification, total RNA was taken and an 
RNA-Seq library constructed as described above using barcoded RNA adapters. Cytoplasmic 
ribosomal RNAs (18S and 28S) were depleted using NEBNext ribosomal RNA depletion kit 
(NEB E6310L) per manufacturers recommendations. Demultiplexed reads were aligned using 
Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml) to custom genomes encoding 
classical noncoding RNAs (ncRNAs) or human messenger RNAs (mRNAs). Expression levels 
were computed for each mRNA by counting the total number of sequencing reads aligned to the 
mature mRNA. To normalize across the different libraries, we computed the read counts for each 
sample that align to non-spliced structural non-coding RNAs – excluding rRNA but including 
snRNAs, 7SL, 7SK, etc. We then divided each mRNA count by the sum of all ncRNA counts. 
This normalized value for each gene per sample was then converted into a fold-change by 
dividing this normalized value to the mean value for both mock infected samples. The fold 
change of each gene relative to mock was plotted across all mRNAs as a violin plot. 
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Table S1: RNA binding map of SARS-CoV-2 proteins, Related to Figure 1. A table of the 
enrichment level of each SARS-CoV-2 protein (rows) by all significantly enriched 100 
nucleotide windows within human RNAs (columns). All bins with an enrichment p-value<0.001 
and enrichment >3-fold for any of the viral proteins is reported. 
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Highlights 
 
• NSP16 binds mRNA recognition domains of U1/U2 snRNAs and disrupts mRNA 
splicing 
• NSP1 binds in the mRNA entry channel of the ribosome to disrupt protein translation 
• NSP8 and NSP9 bind the Signal Recognition Particle and disrupt protein trafficking 
• These disruptions to protein production suppress the interferon response to infection 
 
 
In brief - SARS-CoV-2 proteins directly engage host RNAs and dysregulate RNA-based processes to 
suppress the interferon response 
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